Satisfaction of HIV-infected Patients Treated With Cabotegravir-rilpivirine Injectable Dual Therapy

Question arises as to whether this new treatment "Cabotegravir-rilpivirineactually" improves patient satisfaction and whether it is well suited to everyone, especially those with a history of irregular follow-up. Also, inconvenience of two intramuscular injections every two months and constraint of care organization could represent a barrier to treatment for some patients.

Inclusion Criteria:HIV-1 infected patientPatient over 18 years of agePatient for whom dual injectable sustained-release cabotegravir-rilpivirine therapy is implemented according to the decision of the referring physician in the context of care.Patient who understands, reads and writes French wellExclusion Criteria:Patient opposing to participate in the study.Patient subject to legal protection measures (guardianship, curatorship or safeguard of justice)